CCO Independent Conference Coverage
2005 Annual Meeting of the American Association for the Study of Liver Diseases*
November 11-15, 2005 | San Francisco, CA
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
Latest Findings in HBV Management
|
Track 1 of 4
|
|
|
|
   |
- Geoffrey M. Dusheiko, MD, FCP(SA), FRCP
- Robert G. Gish, MD
- Emmet B. Keeffe, MD, MACP
|
 | |
|
|
HCV Management: Facing New Challenges
|
Track 2 of 4
|
|
|
|
   |
- Gary L. Davis, MD
- Jean-Michel Pawlotsky, MD, PhD
- Mitchell L. Shiffman, MD
|
|
|
Addressing Side Effects and Coinfections
|
Track 3 of 4
|
|
|
|
   |
- Nezam H. Afdhal, MD, FRCPI
- Raymond T. Chung, MD
- Mark S. Sulkowski, MD
|
|
|
Managing HCC and Liver Transplantation
|
Track 4 of 4
|
|
|
|
   |
- Norah Terrault, MD, MPH
- Paul Martin, MD
- Robert J. Fontana, MD
|
|
|
Expert Highlights (mp3)
Listen to the experts quickly summarize the most important data from the conference!
These audio files are in mp3 format. To listen to the audio, simply click "Download Audio." You must be logged onto the clinicaloptions.com site to listen to or download the mp3 files.
|
Robert G. Gish, MD, provides an overview of the data from key studies in HBV presented at the conference. (4 minutes)
|
 |
Download Audio |
|
Mitchell L. Shiffman, MD, reviews the latest antiviral therapies, and high-dose treatment strategies for the management of HCV infection. (2 minutes)
|
|
Download Audio |
|
Raymond T. Chung, MD, discusses the issue of acute HCV infection in HIV-infected patients. (5 minutes)
|
|
Download Audio |
|
Mark S. Sulkowski, MD, discusses the effects of interferon treatment on fibrosis in HCV/HIV coinfected patients. (2 minutes)
|
|
Download Audio |
CCO Daily News (Not required for CME credit)
November 15, 2005 November 14, 2005 November 13, 2005
Disclaimer:
The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
Capsule Summary:
Valopicitabine Plus Peginterferon Alfa-2a Highly Effective at Suppressing HCV in Peginterferon Plus Ribavirin Nonresponders
Valopicitabine plus peginterferon alfa-2a demonstrated significantly greater anti-HCV activity than retreatment with peginterferon plus ribavirin in nonresponders with chronic hepatitis C, according to interim results of a randomized, open-label, multicenter, phase 2b trial.
CLICK HERE TO KEEP READING
CLICK HERE FOR RELATED CAPSULE SUMMARIES
|